» Subscribe Today!
More of what you want to know.
The Daily News

Forgot your password?
TDN Services
Research millions of people and properties [+]
Monitor any person, property or company [+]

Skip Navigation Links
Search results for 'Novartis' | Search again
DeSoto Public Records:1
Shelby Public Records:3
West Tennessee:0
Middle Tennessee:1
East Tennessee:5

You must be a subscriber to see the full results of your search.

Please log in or subscribe below if you are not already a subscriber.

The Daily News subscribers get full access to more than 13 million names and addresses along with powerful search and download features. Get the business leads you need with powerful searches of public records and notices. Download listings into your spreadsheet or database.

Learn more about our services | Search again

Editorial Results (free)

1. Swiss Giant Novartis to Buy US-Based Avexis in $8.7B Deal -

GENEVA (AP) – Swiss pharmaceuticals giant Novartis says it has agreed to buy the U.S.-based gene therapy company AveXis Inc. for $8.7 billion, part of its goal to become a leader in the treatment of neurodegenerative diseases.

2. US Clears First 'Living Drug' for Tough Childhood Leukemia -

WASHINGTON (AP) – Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia.

3. High Court Ruling Speeds Up Generic Biotech Drug Approval -

WASHINGTON (AP) – A unanimous Supreme Court is speeding up the time for generic biotech drugs to become available to the public in a ruling that means a loss of billions in sales to the makers of original versions.

4. Justices Hear Dispute Over Lower-Cost Biotech Drugs Sales -

WASHINGTON (AP) – The Supreme Court on Wednesday considered a drug company's fight to keep a generic version of its biotech drug off the market for an additional six months that would mean billions more in sales and higher costs to the public.

5. Pfizer, Allergan $160B Deal Forms World's Largest Drugmaker -

Pfizer and Allergan are joining in the biggest buyout of the year, a $160 billion stock deal that will create the world's largest drugmaker.

It's also the largest so-called inversion, where an American corporation combines with a company headquartered in a country with a lower corporate tax rate, saving potentially millions each year in U.S. taxes.

6. Pfizer, Allergan in Deal Talks to Create Drug Giant -

TRENTON, N.J. (AP) — Pfizer and Botox maker Allergan are discussing a potential deal that could be the biggest of 2015, a year marked by a rapid-fire pace of megadeals, particularly in health care.

7. GTx Names New Medical Director -

Dr. Diane C. Young is the new vice president, chief medical officer, of GTx Inc.

The Memphis-based biopharmaceutical company announced Young’s appointment Wednesday, July 8.

8. GTx Names New Medical Director -

Dr. Diane C. Young is the new vice president, chief medical officer, of GTx Inc.

The Memphis-based biopharmaceutical company announced Young’s appointment Wednesday, July 8.

9. British Drugmaker Cutting Hundreds of US Jobs -

TRENTON, N.J. (AP) – Hundreds of British drugmaker GlaxoSmithKline's 17,000 U.S.-based employees will lose their jobs by the end of next year under the pharmaceutical industry's latest restructuring.

10. AstraZeneca Rejects $119 Billion Offer From Pfizer -

LONDON (AP) – The board of AstraZeneca on Monday rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that caused a sharp slide in the U.K. company's share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.

11. New Coupons Aim to Keep People Off Generic Drugs -

TRENTON, N.J. (AP) – If brand-name prescription medicines cost you as little as generic pills, which would you choose? A few drugmakers are betting Americans will stick with the name they know.

12. Health Care Stocks Endure Turmoil Better Than Most -

Health care stocks historically provide a relatively safe haven in roiling markets. They're less tethered to the economy's every movement than other stocks and tend to be less volatile.

Anxious investors might be considering putting money in the sector, but the current outlook is complicated by uncertainty over the government's changing involvement in health care. The wild card is potential cuts to Medicare or Medicaid, soon to be considered by Congress' new debt-reduction supercommittee.

13. Unemployment Claims Drop Sharply to 434K -

WASHINGTON (AP) – Fewer people applied for unemployment benefits last week, the second drop in a row and a hopeful sign the job market could be improving.

Still, economists cautioned that the trend would have to continue for several more weeks before a solid conclusion could be drawn that hiring is picking up.

14. Tenn. Federal Judge Won't Dismiss Jaw Injury Cases -

NASHVILLE, Tenn., (AP) - A federal judge refused to dismiss 40 lawsuits against a Swedish-based pharmaceutical company accused of failing to warn patients that two of its drugs can cause severe jaw deterioration.

15. FDA Drug Approvals Mostly Flat in 2009 -

WASHINGTON (AP) - New drugs cleared by the U.S. Food and Drug Administration last year kept pace with 2008, suggesting a much-touted push for drug safety has not slowed down approvals.

The FDA's new leaders did step up early warnings about potential drug safety issues and citations to companies that violate safety regulations.

16. Vaccines on Horizon for AIDS, Alzheimer's, Herpes -

MARIETTA, Pa. (AP) - Malaria. Tuberculosis. Alzheimer's disease. AIDS. Pandemic flu. Genital herpes. Urinary tract infections. Grass allergies. Traveler's diarrhea. You name it, the pharmaceutical industry is working on a vaccine to prevent it.

17. Innova Courts Insurance Cos. For $20 Million -

Instead of taking it easy during the holidays, Innova officials will be calling on the corporate offices of insurance companies in a quest to raise $20 million by Jan. 1.

Insurance companies that invest with Innova Fund II LP – one of six venture funds selected Friday for a new state economic development initiative – will receive tax credits. The credits will allow insurance companies to offset a portion of their premium tax liabilities while they provide funding for fast-growth startup ventures.

18. FDA Scrutinizes Infection Risk with Amgen Drug -

WASHINGTON (AP) - Federal health officials are questioning increased infection rates and tumors seen with an osteoporosis drug from Amgen that analysts say is key to the company's growth.

The U.S. Food and Drug Administration said Tuesday that patients taking Amgen Inc.'s denosumab were more likely to develop infections of the skin, ear and urinary tract than patients taking placebo.

19. Drug Industry, Pfizer Lead in Health Lobbying -

WASHINGTON (AP) - The drug industry's trade group and one of the nation's biggest pharmaceutical companies reported spending more money than other health care organizations on lobbying in the second quarter of this year.

20. Merck, Portola in $470M Deal for Anticlotting Drug -

TRENTON, N.J. (AP) - Merck & Co. and Portola Pharmaceuticals Inc. said Thursday they have signed an exclusive deal to develop and market an experimental drug to prevent strokes in people with a dangerous irregular heart rhythm.

21. Drugmakers Rush to Produce a Swine Flu Vaccine -

LONDON (AP) - With swine flu now an official pandemic, the race is on among drugmakers to produce a vaccine.

GlaxoSmithKline said Thursday after the World Health Organization declared a global flu epidemic that it would be ready within weeks to begin large-scale vaccine production. Sanofi-Aventis also said it had started working on its own version. On Friday, Swiss pharma giant Novartis announced it had created an experimental vaccine that has not been tested in people. Novartis' vaccine was made via a cell-based technology that may prove faster than the traditional way of making vaccines, which relies on chicken eggs.

22. Vaxent Named Finalist In World Vaccine Competition -

The selection committee of the World Vaccine Congress put Vaxent – a startup venture in Memphis with only two employees – alongside pharmaceutical giants Merck, Wyeth, Novartis and Sanofi Pasteur as a finalist for the Best Prophylactic Vaccine award.

23. Vaxent Named Finalist In World Vaccine Competition -

The selection committee of the World Vaccine Congress put Vaxent – a startup venture in Memphis with only two employees – alongside pharmaceutical giants Merck & Co., Wyeth, Novartis and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, as a finalist for the “Best Prophylactic Vaccine” award.

24. Glaxo Buys Stiefel Laboratories for $2.9 Billion -

LONDON (AP) - British drug maker GlaxoSmithKline PLC said Monday it will pay $2.9 billion to buy American dermatology business Stiefel Laboratories Inc. – the latest deal in a flurry of mergers and acquisitions in the pharmaceuticals industry.

25. Avoiding the Ax: Where the Jobs Are -

While the employment landscape looks sparse right now, the outlook for 2009 isn't uniformly bleak – and is downright bright in some recession-resistant industries.

Employers that provide necessary products and services – hospitals and insurers, for example – tend to always need recruits. And areas employers deem critical to their survival, like accounting and information technology, rarely get cut. What's more, some fields, such as bankruptcy law and crisis-management consulting, are thriving because of the downturn.

26. Archived Article: Briefs - Memphis-based Accredo Health Inc

Memphis-based Accredo Health Inc. said its wholly owned subsidiary, Nova Factor Inc., was selected by Genentech Inc. and Novartis Pharmaceuticals Corp. as one of five specialty pharmacy providers of Xolair.


27. Archived Article: Daily Digest - Crichton College

Crichton College

hosts Gandhis grandson

Students at Crichton College will learn more about Mohandas Karamchand Mahatma Gandhi when his grandson, Arun, speaks at 10 a.m. Feb. 3 in the Virgil Iles Auditorium. This lecture is ...

28. Archived Article: Claritin P2 - Claritin copycats might hit market soon

Claritin copycats might hit market soon
A federal judge ruled patent claims on a derivative of allergy drug Claritin are invalid, a decision that could enable rival firms to sell copycat forms of Scher...

29. Archived Article: Comm Focus - Local businesses Save the Day Local businesses Save the Day Campaign gives local businesses the opportunity to help the American Red Cross aid disaster victims By Daphne J. Thomas of the American Red Cross Local businesses can continue to help the A...

30. Archived Article: Ac Humko - Bionutrics, Inc Humko, Bionutrics enter $8 million alliance Bionutrics Inc., biopharmaceutical developer, announced an $8 million transaction with AC Humko Corp. of Memphis. The parties have closed on the sale to AC Humko of $4 million of Bionutrics...

31. Archived Article: Tech Briefs - Ben C Ben C. Bryant, president, chief executive officer and vice chairman of the board of SCB Computer Technology Inc., has given the University of Memphis an endowment of $500,000 to establish the SCB Center for Global Information Technology. The e...